Although cyclophosphamide and corticosteroids have effects on B-cells, the advent of B-cell directed therapies using specific antibodies against CD20, CD22, and against B-cell survival factors and cytokines (anti-BAFF, anti-BR3, TACI-Ig, anti-IL10, anti-IL6), or agents modulating B-cell receptor strength (LJP394, Epratide) provide different mechanisms of action, potential different efficacies and different adverse events
Although cyclophosphamide and corticosteroids have effects on B-cells, the advent of B-cell directed therapies using specific antibodies against CD20, CD22, and against B-cell survival factors and cytokines (anti-BAFF, anti-BR3, TACI-Ig,…